As patient access grows more complex, traditional patient support models are no longer sufficient to meet evolving payer, provider and patient demands. Programs must now balance operational efficiency with adaptability, personalization and measurable impact. The challenge facing life sciences organizations is how to evolve patient support from a reactive service function into a strategic capability that drives insight, access and sustained therapy success.
In this Drug Channels Institute article, Vice President of Business Development Brok Vandersteen explains how patient support programs must evolve into highly sophisticated, tech-enabled operations that integrate data, configurable workflows and advanced analytics to meet future access and performance expectations. Vandersteen also highlights the importance of combining flexible technology with specialized talent to proactively navigate shifting payer policies, personalize patient engagement and deliver real-time insights that demonstrate program value.
Drug Channels Institute is one of the industry’s leading publications offering expert insights on pharmaceutical economics and the drug distribution systems.